Shares of BioLine Rx $BLRX surged in premarket hours amid high volume trading after it announced that it has inked an exclusive worldwide in-licensing agreement with BGN Technologies and Hadasit for a novel treatment intended for liver failure conditions such as �end-stage liver disease�(ESLD) and for conditions potentially leading to liver failure such as�non-alcoholic steatohepatitis�(NASH). This new treatment BL-1220, is the second project in-licensed under the framework of the Company's strategic partnership with Novartis Pharma AG for the screening and development of novel drug candidates.